Mbrx Stock Forecast Zacks
This shows that analyst sentiment has improved and the company's earnings outlook is stronger. The firm presently has a $3.00 target price on the stock.


Zacks investment researchs price objective points to a potential upside of 6.01% from the stocks current price.



Mbrx stock forecast zacks. Moleculin biotech (mbrx) quote overview » charts » moleculin biotech (mbrx) price and consensus. You can see the complete list of today’s zacks #1 rank (strong buy) stocks here. Moleculin biotech nasdaq updated dec 4, 2021 12:42 am.
This chart shows the closing price for mbrx for the last year in relation to the current analyst high, average, and low pricetarget. A rank of 30 means that 70% of stocks appear more favorable to. Moleculin biotech last issued its earnings data on november 11th, 2021.
The firm presently has a $3.00 target price on the stock. Elsewhere, the dow lost 0. View all zacks #1 ranked stocks.
Mbrx moleculin biotech — stock price and discussion | stocktwits. Simply put, stocks with a zacks rank of 1, 2, or 3, with a positive esp were shown to positively surprise 70% of the time. This move lagged the s&p 500's daily gain of 0.5%.
Today, you can download 7 best stocks for the next 30 days. Since then, mbrx shares have decreased by 30.4% and is now trading at $2.11. Is (mbrx) outperforming other medical stocks this year?
Want the latest recommendations from zacks investment research? Earnings for moleculin biotech are expected to decrease in the coming year. Is (mbrx) outperforming other medical stocks this year?
The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The reported ($0.15) eps for the quarter, beating the consensus estimate of ($0.20) by $0.05. Moleculin biotech cs is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart.
Moleculin biotech (nasdaq:mbrx) was upgraded by zacks investment research from a hold rating to a buy rating in a research note issued on thursday, zacks.com reports. Zacks investment researchs price objective points to a potential upside of 6.01% from the stocks current price. To follow mbrx in the coming trading sessions, be sure to utilize zacks.com.
Moleculin biotech has generated $0.00 earnings per share over the last year. Moleculin biotech (nasdaq:mbrx) was upgraded by zacks investment research from a hold rating to a buy rating in a research note issued on thursday, zacks.com reports. Investorsobserver gives moleculin biotech cs (mbrx) an overall rank of 30, which is below average.








Komentar
Posting Komentar